Featured labs address challenges by streamlining processes, reducing costs and optimizing operations while ensuring delivery of care
- Featured labs address challenges by streamlining processes, reducing costs and optimizing operations while ensuring delivery of care
- Digital tools and data-based analytics facilitate operational and clinical decision-making beyond the lab
CHICAGO, July 31, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) will launch its presence at the American Association for Clinical Chemistry (AACC) 2018 Clinical Lab Expo at the McCormick Place Convention Center today by showcasing how laboratories are driving change at integrated health networks by turning challenges associated with the Protecting Access to Medicare Act (PAMA) into opportunities to optimize both lab operations and clinical decision-making processes.
The Roche booth (#1212) will feature presentations about thought-leading labs that have performed comprehensive analyses of their service systems and then streamlined processes to improve productivity, reduce costs and successfully address the reimbursement impact of PAMA and other factors. In the process, they have used lab-based data to impact key institution-wide metrics.
At its media briefing at the convention, Roche management will address new initiatives in the company’s digital diagnostics portfolio that focus on workflow and clinical decision support. In addition, a representative from a Chicago-area health network will discuss how the laboratory is harnessing data to drive decisions that have broad impact beyond the lab, such as reducing the incidence of healthcare-associated infections and the unnecessary use of antibiotics.
The Roche booth will also feature the latest solutions from the company’s entire clinical lab portfolio, including chemistry, molecular, tissue and point-of-care diagnostics, automation and digital diagnostics. The automation area will include a fully automated configuration of an integrated core lab that consolidates routine chemistry and molecular testing.
Highlighted products in the booth include:
- cobas e 801 module - high-volume immunoassay platform that provides nearly twice the throughput on the same footprint as its predecessor.
- cobas c 513 analyzer--fully automated chemistry platform that raises the standard in HbA1c testing throughput.
- cobas 6800 system--fully automated, moderate-complexity platform that brings transformational efficiency gains to molecular diagnostics.
- cobas Connection Module (CCM)--high-volume automation solution that provides connectivity across disciplines and third-party platforms.
- cobas Liat PCR system--point-of-care analyzer with CLIA-waived, real-time PCR tests for flu A/B, flu A/B + RSV and strep A that provide lab-quality results in 20 minutes or less.
- cobas m 511 integrated hematology analyzer--automated system that uses a standardized slide-making and staining process, digital multi-spectral imaging and advanced algorithms to optimize cell counting and classification.
The booth also includes a futures area that offers a glimpse into diagnostics products that are not yet available for sale in the U.S.
In addition, Roche is continuing its commitment to discussing critical industry issues by sponsoring four workshops in conjunction with the AACC 2018 annual meeting:
1. Enabling data-driven decisions to impact change
Tuesday, July 31, 11:30 am - 12:30 pm, Exhibit Hall, Theatre 3
William Morice, MD, PhD
President, Mayo Medical Laboratories
2. Strategically Transforming Molecular Testing Today: Centralization of Routine Testing and Decentralization of Urgent Testing
Tuesday, July 31, 5:30-7:30 pm, Marriott Marquis, Great Lakes Ballroom ABC (Level 2)
Moderator:
Gregory Tsongalis, PhD
Professor of Pathology; Director, Laboratory for Clinical Genomics and Advanced Technology
Dartmouth Hitchcock Medical Center and The Audrey and Theodor Geisel School of Medicine at Dartmouth
Speakers:
John Longshore, PhD
Director of Molecular Pathology
Carolinas Pathology Group and Carolinas Health Systems
Jeffrey Gregg, MD
Associate Professor of Pathology; Director of Molecular Diagnostics
University of California Davis
Nathan Ledeboer, PhD
Professor and Vice Chair of Pathology; Medical Director, Clinical Microbiology; Medical Director, Molecular Diagnostics
Medical College of Wisconsin
3. New Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome
Wednesday, Aug. 1, 7:00 am - 8:30 am, Marriott Marquis, Grand Horizon Ballroom (Level 4)
Fred S. Apple, PhD, DABCC, FACSM
Medical Director of Clinical Laboratories, Hennepin County Medical Center
Professor Laboratory Medicine and Pathology, University of Minnesota School of Medicine
Amy K. Saenger, PhD, DABCC
Associate Professor, Department of Laboratory Medicine and Pathology
University of Minnesota Health
Torbjørn Omland, MD, PhD, MPH
Professor of Medicine, University of Oslo, Division of Medicine
Akershus University Hospital
Richard Body, MB ChB, MRCSEd(A&E), FRCEM, PhD
Professor of Emergency Medicine
University of Manchester
4. Sepsis to stewardship: right answer, right treatment, right outcome
Wednesday, Aug. 1, 11:30 am - 12:30 pm, Exhibit Hall, Theatre 1
Nam Tran, PhD
Director of Clinical Chemistry and Point-of-Care Testing, UC Davis Health
Lance Peterson, MD
Director of Microbiology and Infectious Disease Research, NorthShore University HealthSystem
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com or usdiagnostics.roche.com.
All trademarks used or mentioned in this release are protected by law.
For further information, please contact:
Mike Weist Communications Business Partner Roche Diagnostics Corporation Indianapolis, Indiana USA 317.371.0035 mobile mike.weist@roche.com
View original content:http://www.prnewswire.com/news-releases/roche-to-showcase-how-labs-are-driving-change-across-health-networks-to-address-pama-and-other-challenges-at-aacc-2018-clinical-lab-expo-300689016.html
SOURCE Roche Diagnostics
Company Codes: OTC-PINK:RHHBY, Swiss:RO, Swiss:ROG, OTC-QX:RHHBY
